Cumberland Pharmaceuticals
Patents, Design & Utilities
Last updated:
List of all Cumberland Pharmaceuticals patents 26 in total
| Status | Patent |
|---|---|
Application | Utility: INJECTABLE SOLUTION OF NOREPINEPHRINE Filling date: 26 Sep 2025 Issue date: 28 Jul 2022 |
Application | Utility: Thromboxane Receptor Antagonists in AERD/Asthma Filling date: 26 Sep 2025 Issue date: 14 Jul 2022 |
Application | Utility: Thromboxane Receptor Antagonists in AERD/Asthma Filling date: 26 Sep 2025 Issue date: 7 Jul 2022 |
Application | Utility: Ifetroban Treatment for Systemic Sclerosis Filling date: 26 Sep 2025 Issue date: 5 May 2022 |
Application | Utility: Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban Filling date: 26 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: STABILIZED STATIN FORMULATIONS Filling date: 26 Sep 2025 Issue date: 15 Apr 2021 |
Grant | Utility: Compositions and methods of treating cardiac fibrosis with ifetroban Filling date: 26 Sep 2025 Issue date: 23 Feb 2021 |
Application | Utility: Ifetroban Treatment for Systemic Sclerosis Filling date: 26 Sep 2025 Issue date: 21 Jan 2021 |
Application | Utility: Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists Filling date: 26 Sep 2025 Issue date: 3 Dec 2020 |
Application | Utility: STABILIZED STATIN FORMULATIONS Filling date: 26 Sep 2025 Issue date: 8 Oct 2020 |
Grant | Utility: Doses and methods for administering telavancin Filling date: 26 Sep 2025 Issue date: 25 Aug 2020 |
Application | Utility: INJECTABLE IBUPROFEN FORMULATION Filling date: 26 Sep 2025 Issue date: 20 Aug 2020 |
Application | Utility: Ifetroban Treatment for Systemic Sclerosis Filling date: 26 Sep 2025 Issue date: 13 Aug 2020 |
Application | Utility: Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists Filling date: 26 Sep 2025 Issue date: 4 Jun 2020 |
Application | Utility: Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban Filling date: 26 Sep 2025 Issue date: 21 May 2020 |
Application | Utility: Thromboxane Receptor Antagonists in AERD/Asthma Filling date: 26 Sep 2025 Issue date: 21 May 2020 |
Application | Utility: Acetylcysteine Compositions and Methods of use Thereof Filling date: 26 Sep 2025 Issue date: 23 Apr 2020 |
Application | Utility: Ifetroban Treatment for Systemic Sclerosis Filling date: 26 Sep 2025 Issue date: 16 Apr 2020 |
Grant | Utility: Compositions and methods of treating cardiac fibrosis with ifetroban Filling date: 26 Sep 2025 Issue date: 10 Mar 2020 |
Application | Utility: Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists Filling date: 26 Sep 2025 Issue date: 30 Jan 2020 |
Application | Utility: Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists Filling date: 26 Sep 2025 Issue date: 14 Nov 2019 |
Application | Utility: Ifetroban Treatment for Systemic Sclerosis Filling date: 26 Sep 2025 Issue date: 14 Nov 2019 |
Grant | Utility: Compositions and methods of treating muscular dystrophy with thromboxane-A.sub.2 receptor antagonists Filling date: 26 Sep 2025 Issue date: 29 Oct 2019 |
Application | Utility: Acetylcysteine Compositions and Methods of use Thereof Filling date: 26 Sep 2025 Issue date: 5 Sep 2019 |
Application | Utility: Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists Filling date: 26 Sep 2025 Issue date: 15 Aug 2019 |
Application | Utility: Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban Filling date: 26 Sep 2025 Issue date: 15 Aug 2019 |
Showing 1 to 26 of 26 patents.